Adding vemurafenib doubles progression-free survival in BRAF metastatic colorectal cancer

(University of Colorado Anschutz Medical Campus) Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) to treatment with cetuximab and irinotecan (anti-EGFR) in patients with metastatic colorectal cancer that have a BRAF V600E mutation.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news